Genetic interstitial lung disease

Genetic interstitial lung disease (ILD) is a broad group of rare inherited disorders characterized by inflammation and/or fibrosis of the lung interstitium — the tissue and space surrounding the air sacs (alveoli) of the lungs. These conditions impair gas exchange, leading to progressive respiratory insufficiency. Genetic ILD encompasses a heterogeneous collection of disorders caused by mutations in various genes involved in surfactant metabolism (such as SFTPC, SFTPB, ABCA3, and NKX2-1), telomere biology (TERT, TERC, RTEL1, PARN), and other pathways critical to lung structure and function. Because this is a grouping category rather than a single disease entity, the clinical presentation, severity, and age of onset vary widely depending on the specific underlying genetic cause. Key symptoms commonly include progressive dyspnea (shortness of breath), chronic cough, tachypnea (rapid breathing), hypoxemia (low blood oxygen levels), failure to thrive in infants and children, and exercise intolerance. On imaging, patients typically show ground-glass opacities, reticular patterns, or honeycombing on high-resolution CT scans. In neonates and infants, surfactant dysfunction mutations (particularly SFTPB and ABCA3) can present as severe respiratory distress syndrome shortly after birth, while mutations in SFTPC or telomere-related genes may manifest later in childhood or adulthood as chronic progressive pulmonary fibrosis. Treatment depends on the specific genetic subtype and severity. Supportive care includes supplemental oxygen, pulmonary rehabilitation, and nutritional support. Pharmacological options may include systemic corticosteroids, hydroxychloroquine, and azithromycin, though responses are variable and often suboptimal. For severe or end-stage disease, lung transplantation remains the definitive treatment option. Genetic counseling is recommended for affected families. Research into targeted therapies is ongoing, but no gene-specific curative treatments are currently available for most forms of genetic ILD.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Genetic interstitial lung disease